Old Web
English
Sign In
Acemap
>
authorDetail
>
A Donahue
A Donahue
Pfizer
Germline mutation
Oncology
Avelumab
Hazard ratio
Proportional hazards model
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
225 Avelumab alone in platinum-resistant/refractory ovarian cancer: selected biomarker analyses from the JAVELIN Ovarian 200 trial
2021
E. Pujade-Lauraine
Jonathan A. Ledermann
Amit M. Oza
R Kristeleit
I.L. Ray-Coquard
G. Richardson
C. Sessa
Kan Yonemori
Sushmita Banerjee
Alexandra Leary
X Mu
Yin Liu
K Ching
S. Deng
J Perkins Smith
A Donahue
Keiichi Fujiwara
Bradley J. Monk
Show All
Source
Cite
Save
Citations (0)
229 Avelumab combined with pegylated liposomal doxorubicin in platinum-resistant/refractory ovarian cancer: biomarker analyses from JAVELIN Ovarian 200
2021
E. Pujade-Lauraine
Jonathan A. Ledermann
Amit M. Oza
R Kristeleit
I.L. Ray-Coquard
G. Richardson
C. Sessa
Kan Yonemori
Sushmita Banerjee
Alexandra Leary
X Mu
Yin Liu
K Ching
S. Deng
J Perkins Smith
A Donahue
Keiichi Fujiwara
Bradley J. Monk
Show All
Source
Cite
Save
Citations (0)
1